Introduction

▼
Glucocorticoids, natural and synthetic, are adrenocortical steroids readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), are used as replacement therapy in adrenocortical defi ciency states. Their synthetic analogues are primarily used for their anti-infl ammatory eff ects in disorders of many organ systems. A derivative of prednisolone, betamethasone (BMZ), has a 16β-methyl group that enhances the anti-infl ammatory action of the molecule. BMZ sodium phosphate (CAS No: 151-73-5), a soluble ester, provides rapid activity, while BMZ acetate (CAS No: 987-24-6) is only slightly soluble and supplies sustained activity [ 1 -6 ] . Betamethasone injectable suspension is a sterile aqueous suspension containing BMZ 3 mg/mL as BMZ sodium phosphate, and BMZ acetate 3 mg/mL. When oral therapy is not possible, the intramuscular use of BMZ sodium phosphate and BMZ acetate injectable suspension is indicated in allergic states, ■ Proof copy for correction only. All forms of publication, duplication or distribution prohibited under copyright law. ■
Materials and Methods
▼
Materials
Methanol and dichloromethane were HPLC grade and purchased from Merck Company (Darmstadt, Germany). Hydrocortisone and betamethasone powders were provided form Fluka Chemica (Milano, Italy). The test formulation was betamethasone injectable suspension manufactured by Exir, Boroujerd, Iran with a batch number of 0150605, and the reference formulation was from respected manufacturer with a batch number of 5AHUB02A02 respectively.
Methods
Study design
24 healthy male volunteers who had given written informed consent were enrolled in the trial and completed both treatment periods. The mean ± SD age was 24.4 ± 3.1 years (20-33 years) and the mean ± SD body weight was 71.0 ± 7.3 Kg (60-89 Kg). To qualify the study, subjects had to be in acceptable physical condition as evidenced by absence of abnormal fi ndings on physical examination. The mercury sphygmomanometer device was used for blood pressure measurement. When taking the measurement from the right upper arm, the arm was supported so that the cuff was at the level of the right atrium with the arm straight and the antecubital fossa faces upward. The radial artery was used as the pulse point to determine subjects' heart rate. The study used an open label, randomized, 2 period and cross over design. The 2 treatment days were separated by a 2-week washout period. This study was carried out in accordance with the principles of the World Medical Association's Declaration of Helsinki and its amendments and was approved by the local ethical committee of Tabriz University of Medical Sciences (5/4/2402). The volunteers received an intramuscular injection of either long acting formulation containing betamethasone (as disodium phosphate) equivalent to 3 mg/1 mL and betamethasone acetate 3 mg/1 mL. Inactive ingredients per mL of each formulation include 7.1 mg dibasic sodium phosphate; 3.4 mg monobasic sodium phosphate; 0.1 mg edetate disodium; and 0.2 mg benzalkonium chloride as preservative. The pH was between 6.8 and 7.2. Blood samples (7 mL) for pharmacokinetic evaluations were obtained just before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after dosing during each treatment period. Samples were centrifuged at 5 000 for 5 min. Plasma samples were separated and stored at − 20 °C until analysis. The time interval between collecting the blood samples and their analysis was less than 1 month. Results of preliminary study confi rmed the stability of drug during this time in frozen samples. For drug analysis frozen samples were thawed at room temperature and then 50 μL of Internal Standard (IS) solution (Hydrocortisone acetate, 500 ng/mL) and 5 mL of dichloromethane were added to 1 mL of plasma. The solution was centrifuged at 5 000 rpm for 5 min and then dichloromethane phase was separated and evaporated at 45 °C. Residue was dissolved in 250 μl of mobile phase and 200 μL of it was injected into chromatographic column. A high performance liquid chromatographic method previously developed by Petersen et al. [ 14 ] , was used for plasma drug concentration measurement. Liquid chromatographic system (Shimadzu, Japan) comprising a variable wavelength ultraviolet spectrophotometric detector set at 254 nm was used. Separation column was Shimpack CLC C8 (5 μm, 250 × 4.5 mm) (Shimadzu, Columbia, MD). Mobile phase consisted of methanol and water, 65:35 (v/v %). At fl ow rate of 1.5 mL/min, retention time for BMZ and IS was 4.9 and 5.5 min respectively. A calibration curve was established from analyzing spiked samples, which are obtained by the addition of known quantities of BMZ to plasma. The standard concentrations of BMZ were 1.56, 3.125, 6.25, 12.5, 18.75 and 25 ng/mL. The peak area ratio of BMZ to IS was plotted against the standard sample concentrations. The precision and accuracy of the method were assessed in plasma by performing replicate analysis of quality control (QC) samples at 4 levels (5, 10, 15, and 25 ng/mL), 4 time in a day and in 4 consecutive days. Extraction recovery of BMZ from plasma samples were determined for 3 QC concentrations (6.25, 12.5 and 25 ng/mL) by comparing the peak area obtained from the plasma with the peak area obtained from the direct injection of pure prepared standard solution. Sensitivity parameters, LOD and LOQ were calculated as signal to noise ratios of 3 and 10 respectively [ 15 -19 ] .
A non-compartment pharmacokinetic model was used to obtain pharmacokinetic parameters. The analyzed parameters were the area under the plasma concentration-time curve (AUC), peak plasma concentration (C max ) and time to peak plasma concentration (T max ). The individual subjects' C max was obtained directly from the concentration-time curve, and AUC 0-t was determined using the trapezoidal rule. AUC 0-∞ was calculated as AUC 0-t + C t /k e , where C t was the last measurable plasma drug concentration and k e was the elimination rate constant, obtained as the slope of the linear regression of the log-transformed concentration-time curve data in the terminal phase. The T 1/2 was calculated as ln2/K e . Parametric 90 % confi dence intervals (CIs) based on the ANOVA of the mean test/reference ratios of C max, AUC 0-t , and AUC 0-∞ were determined. If the diff erences in parameters between the 2 formulations were not statistically signifi cant and the 90 % CIs for each parameter was within the predetermined range of 80-125 %, the 2 drugs were to be considered bioequivalent based on US Food and Drug Administration (FDA) guidelines [ 11 -13 , 17 , 20 ] .
Results and Discussion
▼
Several analytical methods such as gas chromatography-MS, liquid chromatography (LC) -tandem mass spectrometry (MS), micellar electrokinetic capillary chromatography (MEKC), Differential-pulse-polarography (DPP), Radioimmunoassay and HPLC method have been used previously to determine BMZ in numerous biological and pharmaceutical samples, e. g., urine, serum, plasma, milk, tissues and diff erent drug formulations [ 15 , 16 , 21 -27 ] . The HPLC method used in this study was [ 7 , 28 ] . Also in Petersen et al.'s study, AUC 0-∞ , T max and C max were 486.33 ng.h/mL, 1.55 h and 55 ng/mL [ 29 ] . However in our study the mean ( ± SD) C max values, were 22.28 ( ± 6.24) ng/mL and 23.81 ( ± 4.72) ng/mL for the test and reference formulation respectively. Corresponding data for T max , were 1.77 ( ± 0.44) and 1.44 ( ± 0.56) h. The AUC 0-t values were 140.21 ( ± 46.58) ng.h/mL and 138.96 ( ± 52.02) ng.h/mL for the test and reference formulation. Corresponding AUC 0-∞ values were 145.75 ( ± 48.26) ng.h/ mL and 141.42 ( ± 54.99) ng.h/mL respectively ( • ▶ Table 3 ).
ANOVA test for these parameters after log-transformation of the data found no statistically signifi cant diff erences between the 2 formulations in period, product or group. 
Conclusion
▼
The mean and standard deviation of C max , AUC 0-t and AUC 0-∞ of the test formulations did not diff er signifi cantly, suggesting that the blood profi les generated by test formulation were comparable to reference formulation. ANOVA for these parameters, after log-transformation of the data, showed no statistically significant diff erence between the 2 formulations either in periods, product or group, having a P-value greater than 0.05. The 90 % CIs also demonstrated that the ratios of C max , AUC 0-t and AUC 0-∞ of the 2 formulations lie within the FDA acceptable range of 80-125 %. Based on the obtained results we can conclude that betamethasone injectable suspension, manufactured by Exir Pharmaceutical Company, Boroujerd, Iran is bioequivalent to reference formulation, and both formulations can be considered equally eff ective and interchangeable in medical practice.
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